- Pfizer announced their experiments on children 6 months and older were unsuccessful in 2- to 5-year-olds as they didn’t produce an immune response, leading to a recommendation for a third shot and delaying the Emergency Use Authorization (EUA) for the youngest citizens.
- Although the experiments produced a strong response in children 6 months to 24 months and 5 to 12 years, the company announced they were evaluating increasing these doses as well.
- The study is listed as a phase 1, 2 and 3 model, evaluating the safety, dose and efficacy simultaneously, a strategy seldom, if ever, used. Data collection and analysis will be completed in one year on a population with little risk of the illness.
- Despite the readily available and public data, some continue to call for a shot for children for the sake of herd immunity. Yet, according to a recent engineering analysis more people have died from the shot in less time than from the disease.’https://childrenshealthdefense.org/defender/pfizer-third-dose-covid-vaccine-toddlers/?utm_source=salsa&eType=EmailBlastContent&eId=940b867a-1d8e-4c5e-87d4-1a063a99ae30